Jacob N. Hunnicutt

Jan 6, 2025 | onlinelibrary.wiley.com | Marleen Bokern |Christopher T. Rentsch |Jennifer K Quint |Jacob N. Hunnicutt

COVID-19 outcomes may have been at risk of misclassification early during the COVID-19 pandemic. No pharmacoepidemiological studies have evaluated the impact of such misclassification on their findings. We used several forms of quantitative bias analysis to adjust for outcome misclassification in an analysis of inhaled corticosteroids and COVID-19 hospitalisation and death. We found that all methods shifted effect estimates away from the null, albeit to a limited extent.

Aug 14, 2024 | medrxiv.org | Marleen Bokern |Christopher T. Rentsch |Jennifer K Quint |Jacob N. Hunnicutt

MPB is funded by a GSK PhD studentship to investigate the application of quantitative bias analysis in observational studies of COVID-19. IJD has unrestricted grants from and shares in GSK. AS is employed by LSHTM on a fellowship funded by GSK. JH was employed by GSK and owned stock in GSK during the conduct of this work. CTR and JQ report no conflicts of interest.